# A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

> **NCT01699464** · PHASE2 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 211 (actual)

## Conditions studied

- Ocular Hypertension
- Open-angle Glaucoma

## Interventions

- **DRUG:** AR-12286 Ophthalmic Solution 0.7%
- **DRUG:** AR-12286 Ophthalmic Solution 0.5%
- **DRUG:** Timolol maleate ophthalmic solution 0.5%

## Key facts

- **NCT ID:** NCT01699464
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01699464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01699464, "A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01699464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*